|
| 36722252 | Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials. | | 2023 |
| 36342827 | Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled. | Circulation | 2023 |
| 36082522 | Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial. | Diabetes, Obesity and Metabolism | 2023 |
| 36325584 | Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. | Eur J Heart Fail | 2023 |
| 36410653 | Increases in Fibroblast Growth Factor 23 During Treatment With Ferric Carboxymaltose: Potential Adverse Effects on the Heart and Kidneys. | Journal of Cardiac Failure | 2023 |
| 36396554 | Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure. | JACC: Heart Failure | 2023 |
| 37755814 | Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management. | JAMA Cardiol | 2023 |
| 37586658 | Sotagliflozin for Heart Failure: What We Know About Trials and Mechanisms. | | 2023 |
| 37902773 | Alleviation of Anemia by SGLT2 Inhibitors in Patients with CKD: Mechanisms and Results of Long-Term Placebo-Controlled Trials. | | 2023 |
| 37559543 | Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors. | | 2023 |
| 37558088 | Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial. | J Card Fail | 2023 |
| 37623429 | Acetazolamide for acute heart failure: is ADVOR a riddle wrapped in a mystery inside an enigma? | | 2023 |
| 37621153 | Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. | Circulation | 2023 |
| 37771260 | Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 36974746 | Health status across major subgroups of patients with heart failure and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 37409733 | Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure. | | 2023 |
| 37407154 | Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan. | JACC Heart Fail | 2023 |
| 37031887 | The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial). | J Card Fail | 2023 |
| 37403655 | Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE. | | 2023 |
| 37340541 | Fetal Reprogramming of Nutrient Surplus Signaling, O-GlcNAcylation, and the Evolution of CKD. | | 2023 |
| 37278451 | Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial. | Eur J Heart Fail | 2023 |
| 37211049 | Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis. | | 2023 |
| 37086098 | Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. | | 2023 |
| 37028749 | Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials. | | 2023 |
| 36583283 | Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. | | 2023 |
| 37401511 | Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. | Eur J Heart Fail | 2023 |
| 37330198 | COUNTERPOINT: the Seductive Trap of Relying on Exaggerated Effects in Short-Term Heart Failure Trials to Predict Benefits and Risks in Patients With Long-Term Disease. | | 2023 |
| 37199158 | Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. | Arterioscler Thromb Vasc Biol | 2023 |
| 37076211 | Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer. | | 2023 |
| 37075940 | The First Dedicated Comprehensive Heart Failure Program in the United States: The Division of Circulatory Physiology at Columbia Presbyterian (1992-2004). | | 2023 |
| 37013269 | A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic features. | | 2023 |
| 36881400 | Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. | JACC Heart Fail | 2023 |
| 36812948 | Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure. | | 2023 |
| 36632831 | Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. | Eur Heart J | 2023 |
| 36565199 | Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. | J Am Heart Assoc | 2023 |
| 36563739 | Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events? | J Card Fail | 2023 |
| 36944496 | Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. | Eur Heart J | 2023 |
| 36943907 | Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial. | Circ Heart Fail | 2023 |
| 36943697 | Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure? | | 2023 |
| 36872213 | Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis. | JACC Heart Fail | 2023 |
| 36478225 | Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. | Eur Heart J | 2023 |
| 36477809 | Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. | JAMA Cardiol | 2023 |
| 37191207 | Incremental prognostic value of biomarkers in PARADIGM-HF. | Eur J Heart Fail | 2023 |
| 37191081 | Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial. | Eur J Heart Fail | 2023 |
| 37062869 | Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE. | Eur J Heart Fail | 2023 |
| 37062866 | Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. | Eur J Heart Fail | 2023 |
| 37062851 | Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial. | Eur J Heart Fail | 2023 |
| 37434410 | Foetal recapitulation of nutrient surplus signalling by O-GlcNAcylation and the failing heart. | | 2023 |
| 37369637 | Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. | Eur J Heart Fail | 2023 |
| 37051752 | Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial. | Eur Heart J | 2023 |